Veeva Systems recently raised its fiscal 2027 revenue guidance to about US$3.65 billion and adjusted EPS outlook to roughly US$9.05, following fiscal Q1 2027 results that exceeded its own guidance and showed stronger profitability helped by expanding AI-driven offerings.
This combination of upgraded full-year targets and growing AI-enabled products has sharpened investor focus on how Veeva’s business model may be evolving toward higher-margin, software-driven growth.
With Veeva lifting its full-year outlook, we’ll now examine how this stronger guidance reshapes the company’s investment narrative and risks.
Invest in the nuclear renaissance through our list of 90 elite nuclear energy infrastructure plays powering the global AI revolution.
Veeva Systems Investment Narrative Recap
To own Veeva, you need to believe that life sciences companies will keep standardizing critical workflows on its cloud platforms and increasingly pay for higher-margin, AI-enhanced software. The recent upgrade to fiscal 2027 guidance reinforces that AI-enabled offerings are contributing meaningfully, which supports the near term catalyst of expanding AI agents across Vault. At the same time, it does little to reduce the core risk that large pharma customers may still adopt competing platforms, pressuring growth and pricing.
Among recent announcements, the preview of Vault AI Agents and the Falcon agentic labor platform looks most relevant, because it ties directly to why guidance was raised. These tools are designed to automate work in areas like clinical operations, safety case handling and quality documentation, which sits at the heart of the AI and margin expansion thesis. How quickly customers adopt these AI capabilities will likely influence whether the upgraded outlook proves conservative or ambitious.
Yet behind the stronger outlook, investors should also be aware of the risk that slower than expected AI adoption across clinical, safety and quality workflows could…
Read the full narrative on Veeva Systems (it’s free!)
Veeva Systems’ narrative projects $4.7 billion revenue and $1.4 billion earnings by 2029. This requires 12.4% yearly revenue growth and an earnings increase of about $0.5 billion from $941.7 million today.
Uncover how Veeva Systems’ forecasts yield a $245.48 fair value, a 32% upside to its current price.
Exploring Other Perspectives 
VEEV 1-Year Stock Price Chart
Before this guidance hike, the most optimistic analysts were already modeling about US$5.0 billion of revenue and US$1.6 billion of earnings by 2029, leaning heavily on faster AI agent adoption. Compared with the more cautious consensus that focuses on CRM concentration and competitive threats, this is a clearly more optimistic story, and the latest AI driven beat and raise could either support or challenge those high expectations as new information comes in.
Explore 12 other fair value estimates on Veeva Systems – why the stock might be worth as much as 72% more than the current price!
Decide For Yourself
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
A great starting point for your Veeva Systems research is our analysis highlighting 3 key rewards that could impact your investment decision.
Our free Veeva Systems research report provides a comprehensive fundamental analysis summarized in a single visual – the Snowflake – making it easy to evaluate Veeva Systems’ overall financial health at a glance.
Interested In Other Possibilities?
Right now could be the best entry point. These picks are fresh from our daily scans. Don’t delay:
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include VEEV.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com